Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
Wilson's purchase increases his total equity stake by 9% following a 62% one-year stock return, signaling confidence in the oncology biotech's pipeline.
Overview
Troy Edward Wilson, the President, Chairman, and CEO of Kura Oncology, Inc. (NASDAQ:KURA), purchased ~100,000 shares of common stock on August 24, 2026. SEC Form 4 filing.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer. The company's portfolio includes Komzifti (ziftomenib), an oral small molecule menin inhibitor, and darlifarnib, which is currently in a Phase 1 trial for solid tumor indications.
Details
Transaction value based on SEC Form 4 weighted average purchase price ($12.39); post-transaction value based on Aug. 24, 2026 market close ($12.40).
Source
Originally published at www.fool.com.